Company Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache.
Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis.
The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain.
It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes.
The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
| Country | United States |
| Founded | 1876 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 43,000 |
| CEO | David Ricks |
Contact Details
Address: Lilly Corporate Center Indianapolis, Indiana 46285 United States | |
| Phone | 317 276 2000 |
| Website | lilly.com |
Stock Details
| Ticker Symbol | LLY |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000059478 |
| CUSIP Number | 532457108 |
| ISIN Number | US5324571083 |
| Employer ID | 35-0470950 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David A. Ricks | Chairman, Chief Executive Officer and President |
| Dr. Daniel M. Skovronsky M.D., Ph.D. | EVice President, Chief Scientific Officer and President of Lilly Research Laboratories and Lilly immunology |
| Anat Hakim J.D. | Executive Vice President, General Counsel and Secretary |
| Jacob S. Van Naarden | Executive Vice President and President of Loxo |
| Lucas E. Montarce | Executive Vice President and Chief Financial Officer |
| Donald A. Zakrowski | Senior Vice President of Finance and Chief Accounting Officer |
| Diogo Rau | Executive Vice President and Chief Information and Digital Officer |
| Alonzo Weems | Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer |
| Eric Dozier | Executive Vice President of Human Resources and Diversity |
| Jeffrey N. Simmons | Senior Vice President and President of Elanco Animal Health |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | 144 | Filing |
| Oct 30, 2024 | 10-Q | Quarterly Report |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 9, 2024 | 8-K | Current Report |
| Aug 26, 2024 | 144 | Filing |
| Aug 22, 2024 | 144 | Filing |
| Aug 16, 2024 | 8-K | Current Report |